Definium Therapeutics (DFTX) is a clinical-stage biopharmaceutical company developing novel therapeutics with potential in multiple disease areas. Key risks include clinical trial failures, regulatory setbacks, dilution from future financing, and typical biotech execution risks.

Definium Therapeutics (DFTX) is positioned for significant growth with promising drug pipeline and clinical developments that could drive the stock to $200. Key risks include clinical trial failures, regulatory challenges, and market competition in the pharmaceutical sector.